Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation

Trial Profile

Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Acronyms ENVISAGE-TAVI AF
  • Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
  • Most Recent Events

    • 08 May 2017 According to a Daiichi Sankyo Company media release, first patients has been enrolled.
    • 27 Apr 2017 According to a Daiichi Sankyo Company media release, first patient has been enrolled in this study.
    • 24 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top